4-[2-(t-Butylamino)-1-hydroxyethyl]phenol (buctopamine, 4), a new β receptor agonist (β-agonist), was found to be an adulterant in feed additives for swine in Taiwan, where using β-agonists in food-production animals is prohibited. Buctopamine and its metabolite, 4-[2-(t-butylamino)-1-hydroxyethyl]-2-methoxyphenol (mebuctopamine, 2), were detected in swine hair specimens. Authentic compounds 2 and 4 were synthesized with 98.6% and 97.7% purity, respectively, as reference standards for analysis, and both compounds were more hydrophilic than ractopamine and clenbuterol. In a preliminary pharmacological evaluation, compounds 2 and 4 exhibited moderate human β receptor binding affinity and did not show significant affinities for the human α, α, β, and β receptors. After addition of compounds 2-4 into the β-agonist library, a multiresidue analysis of 26 β-agonists by using triple quadrupole LC/MS/MS for routine screening conducted by regulatory authorities was established, in which the common limits of quantification for the 26 β-agonists in swine feed and hair are 10 and 25 ng/g, respectively. In addition, the illegal use of buctopamine (4) has been effectively prevented. The results of this study are also useful for controlling the illegal use of new β-agonists in food-production animals.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acs.jafc.7b00130 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!